Citi analyst Joanne Wuensch lowered the firm’s price target on iRhythm (IRTC) to $214 from $242 and keeps a Buy rating on the shares. The firm adjusted targets in the medical technology group post the Q4 reports. Sector fundamentals remain “healthy” despite the recent volatility, the analyst tells investors in a research note. Citi’s top picks are iRhythm and Medtronic.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IRTC:
- iRhythm Technologies Earnings Call Highlights Profitable Surge
- iRhythm price target lowered to $200 from $215 at Truist
- iRhythm price target lowered to $184 from $211 at Goldman Sachs
- iRhythm should be bought on subpoena weakness, says William Blair
- iRhythm says received civil investigative demand from DOJ in December